Syngene International

Syngene International expects a stronger second half of FY27, driven by its order book and Zoetis supplies, while retaining guidance for a single-digit revenue decline.

Syngene International has reported a consolidated net loss of ₹9 crore in Q1 FY27, as against a net profit of ₹86.7 crore in the corresponding quarter previous fiscal.

Syngene International Ltd on Friday said that its Managing Director & Chief Executive Officer, Peter Bains, has resigned as part of leadership succession. Bains has resigned from the position of MD & CEO with effect from the close of business hours on June 30, Syngene International said in a regulatory filing. In his resignation letter to the chairman of the company's board, Bains said he is resigning from his position following "our recent discussions regarding leadership succession and CEO transition". Syngene International is a contract research, development and manufacturing organisation and is part of the Biocon group.

Today's rally in the counter came despite the company reporting a 19 per cent Y-o-Y decline in consolidated net profit to ₹147.9 crore in Q4FY26.

Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows

Syngene International fell as much as 5.7 per cent to ₹559.10, the lowest level since April 5, 2023, on the National Stock Exchange (NSE)

Librela inventory correction and one-time labour code costs weigh on earnings

As regulators ease biosimilar trial norms, Syngene International is expanding into late-stage clinical supply production, betting on biologics and peptide manufacturing for growth

Revenue up 2% YoY to Rs 926 crore as research services offset biologics inventory correction; company maintains FY26 guidance

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Syngene's Q1 FY26 profit rose to Rs 87 crore as Research Services drove contract conversions, while operational revenue rose 11 per cent to Rs 875 crore

Syngene's stock fell as much as 10 per cent during the day to ₹674.25 per share, the worst intraday loss atleast in over five years

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business

The facility, which the contract research firm said is strategically located near key biotech hubs in the Northeast US, is expected to be operational for client projects from the second half of 2025

The facility, equipped with multiple monoclonal antibody (mAbs) manufacturing lines, comes for a deal value of $36.5 million

Pharma stocks list: Divis Labs share price rallied 1.9% intraday, Suven Pharma share price surged 4.6%, Blue Jet Healthcare share price added 4.9%, and Syngene International share price rose 1.5%

During the quarter, Discovery Services launched "China+1" pilots with large and mid-size pharma companies and converted them into long-term contracts. Growth signals stabilizing

Reports suggest promoter Biocon was likely to sell a 2 per cent stake in the company via block deals

Syngene plans to expand its capacity and capabilities at its Bangalore and Hyderabad campuses to meet anticipated long-term demand

Derivatives market update for Sept 06: The Nifty PCR dipped from 0.74, while Bank Nifty to 0.78; reflecting a cautionary trend said Dhupesh Dhameja of SAMCO Securities. Max Financial see short buildup